Coherus Oncology
CHRS
117 hedge funds and large institutions have $50M invested in Coherus Oncology in 2025 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 40 increasing their positions, 32 reducing their positions, and 18 closing their positions.
158% more call options, than puts
Call options by funds: $173K | Put options by funds: $67K
25% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 32
3.47% less ownership
Funds ownership: 56.94% → 53.47% (-3.5%)
6% less funds holding
Funds holding: 124 → 117 (-7)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
45% less capital invested
Capital invested by funds: $90.5M → $50M (-$40.5M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$2.13M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$1.67M |
| 3 |
Citigroup
New York
|
+$623K |
| 4 |
Renaissance Technologies
New York
|
+$588K |
| 5 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$427K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
-$7.29M |
| 2 |
Morgan Stanley
New York
|
-$2.2M |
| 3 |
DGI
Disciplined Growth Investors
Minneapolis,
Minnesota
|
-$782K |
| 4 |
AQR Capital Management
Greenwich,
Connecticut
|
-$629K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$391K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
BCM
126
Bayesian Capital Management
Brooklyn,
New York
| – | -$19.5K | -14,100 | Closed |
|
|
EI
127
Ethic Inc
New York
| – | -$15.7K | -11,397 | Closed |
|
|
BBA
128
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| – | -$13.1K | -10,571 | Closed |
|
|
PFGIA
129
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
| – | -$14K | -10,169 | Closed |
|
130
Mariner
Overland Park,
Kansas
| – | -$13.8K | -10,000 | Closed |
|
131
Russell Investments Group
London,
United Kingdom
| – | -$1.02K | -743 | Closed |
|
|
LFG
132
Larson Financial Group
St Louis,
Missouri
| – | -$203 | -147 | Closed |
|
|
RS
133
R Squared
Central,
Hong Kong
| – | -$193 | -140 | Closed |
|
|
GCL
134
Glazer Capital LLC
New York
| – | +$1 | +1 | New |
|
|
AW
135
Avion Wealth
The Woodlands,
Texas
| – | +$760 | +660 | New |
|
CHRS Hedge Fund Activity: Q1 2025 in Review
117 of the 7,458 institutional investors tracked by Wall St. Rank reported a position in Coherus Oncology (CHRS) for Q1 2025, worth a combined $50M — down 45% from $90.5M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of CHRS and 12 opened new positions — a net loss of 6 holders — while 32 trimmed existing stakes and 40 added.
The largest buyer was Millennium Management, adding an estimated $2.13M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $7.29M sold.
- 117 institutional investors held Coherus Oncology (CHRS) as of Q1 2025, down from 124 in Q4 2024.
- Funds reported $50M of Coherus Oncology stock for Q1 2025, down 45% quarter-over-quarter.
- 12 funds opened new Coherus Oncology positions in Q1 2025 and 18 closed out, a net change of -6 holders.
- The largest Coherus Oncology buyer in Q1 2025 was Millennium Management, an estimated $2.13M added.
- The largest Coherus Oncology seller in Q1 2025 was Point72 Asset Management, an estimated $7.29M sold.
Based on aggregated 13F filings for Q1 2025.